Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...

Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.

Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.

The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked ...

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health ...

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...

NEW YORK, July 26, 2024 /PRNewswire/ -- The global motion sickness drugs market size is estimated to grow by USD 139.5 million from 2024-2028, according to Technavio. The market is estimated to grow ...

If you’re prone to motion sickness, you know the feeling of panic that comes with the onset of symptoms like nausea, dizziness and an upset stomach. Motion sickness manifests in different ways and ...

Motion sickness is caused by movement such as riding in cars, boats, and amusement rides, or by seeing motion on a screen. It can cause nausea and vomiting, but doesn’t typically need medical ...